Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

DOI: 10.1080/2162402X.2015.1094598

Keywords: EML4-ALK, immunotherapy, NSCLC, PD-L1, PD-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text